Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381415 | 0.92 | NPC1L1 (0.45) | NPC1L1HTTSIGMAR1OPRM1OPRL1 | |
| SCHEMBL2380625 | 0.87 | ALDH1A1 (0.41) | NPC1L1POLBCHRM2CHRM3 | |
| SCHEMBL2381294 | 0.87 | L3MBTL1 (0.48) | NPC1L1 | |
| SCHEMBL2310823 | 0.87 | OPRM1 (0.49) | HTTOPRM1OPRL1CHRM2CHRM4 | |
| SCHEMBL2309756 | 0.84 | OPRM1 (0.41) | HTTOPRM1OPRL1 | |
| SCHEMBL2380347 | 0.82 | CYP3A4 (0.46) | NPC1L1HTTOPRM1OPRL1CHRM2 | |
| SCHEMBL2309697 | 0.82 | OPRM1 (0.60) | HTTOPRM1OPRL1 | |
| SCHEMBL2306928 | 0.82 | CA1 (0.48) | NPC1L1HTTOPRM1OPRL1POLB | |
| SCHEMBL2308854 | 0.82 | FNTA (0.48) | HTTOPRM1OPRL1CHRM2CHRM4 | |
| SCHEMBL2308976 | 0.82 | USP2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | claimed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | claimed |
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | NPC1L1 3605/4885HTT 4440/4885SIGMAR1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.